Kinnate Biopharma News

KNTEDelisted Stock  USD 2.96  0.27  8.36%   
About 62% of Kinnate Biopharma's investor base is looking to short. The analysis of current outlook of investing in Kinnate Biopharma suggests that many traders are alarmed regarding Kinnate Biopharma's prospects. The current market sentiment, together with Kinnate Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Kinnate Biopharma stock news signals to limit their universe of possible portfolio assets.
  
over a year ago at globenewswire.com         
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exar...
Macroaxis News: globenewswire.com
over a year ago at finance.yahoo.com         
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exar...
Yahoo News
over a year ago at news.google.com         
Ginkgo Bioworks Holdings Inc Stock What Does the Chart Say Monday - InvestorsObserver
Google News at Macroaxis
over a year ago at www.macroaxis.com         
Payment of 1721 shares by Neha Krishnamohan of Kinnate BiopharmaInc subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
Irenic Sends Letter to Theravance Biopharma Regarding the Urgent ... - Marketscreener.com
Google News at Macroaxis
over a year ago at simplywall.st         
Insiders who bought this year lost US132k as Kinnate Biopharma Inc. sheds US96m in value
Simply Wall St News at Macroaxis
over a year ago at news.google.com         
Acquisition by Orbimed Advisors Llc of 550000 shares of Kinnate BiopharmaInc subject to Rule 16b-3
Google News at Macroaxis
over a year ago at www.macroaxis.com         
Acquisition or disposition of Kinnate BiopharmaInc securities by Tananbaum James B
Macroaxis News
over a year ago at finance.yahoo.com         
Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China...
Yahoo News
over a year ago at benzinga.com         
Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China...
benzinga news
over a year ago at globenewswire.com         
Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China...
Macroaxis News: globenewswire.com
over a year ago at globenewswire.com         
Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China...
Macroaxis News: globenewswire.com
over a year ago at www.macroaxis.com         
Acquisition by Neha Krishnamohan of 215000 shares of Kinnate BiopharmaInc subject to Rule 16b-3
Macroaxis News
over a year ago at investing.com         
Kinnate Biopharma Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN...
Investing News at Macroaxis
over a year ago at benzinga.com         
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration fo...
benzinga news
Far too much social signal, news, headlines, and media speculation about Kinnate Biopharma that are available to investors today. That information is available publicly through Kinnate media outlets and privately through word of mouth or via Kinnate internal channels. However, regardless of the origin, that massive amount of Kinnate data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kinnate Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kinnate Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kinnate Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kinnate Biopharma alpha.

Kinnate Biopharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
06/01/2023
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Consideration for investing in Kinnate Stock

If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals